Encycle Therapeutics, a MaRS Innovation spin-off company, was included in BioCentury‘s companies to watch within the macrocycle chemistry space.
The reference came in Chris Cain‘s article, “Maturing macrocycle chemistry drives explosion of biotech newcos, biopharma deals.”
Hossein Rahnama, CEO of Flybits, a MaRS Innovation spin-off company, appeared on CBC’s Lang and O’Leary Exchange on August 24, 2012.
Watch Rahnama’s interview on CBC’s Media Player. The interview begins at the 13:40 mark and runs to 19:30.
Rahnama, who is also a professor at Ryerson University and and research director at Ryerson’s Digital Media Zone, was recently named to the MIT Technology Review’s prestigious 35 Inventors Under 35 list for 2012 along with fellow MaRS Innovation inventor Joyce Poon.
He describes his context-aware mobile technology, the importance of adapting research to solve real-world problems, the advantages to running a start-up in Toronto, and growing Flybits while keeping the business in Canada.
Professors Joyce Poon and Hossein Rahnama, who each have inventions within MaRS Innovation’s portfolio of spin-off companies and licenseable technologies, have been named to the MIT Technology Review‘s prestigious 35 Inventors Under 35 list for 2012.
Poon, an assistant professor of electrical and computer engineering at the University of Toronto, was recognized for, according to MIT’s Technology Review, “creating new optical modulators with microscopic loop-the-loops through which light can shuttle data between servers and even from chip to chip within a single server.” She is working with MaRS Innovation to license her technology.
Andrew Sinclair, CEO of OtoSim Inc. and a senior director at MaRS Innovation, describes some of the unexpected twists and turns OtoSim has weathered in bringing their product to market in…
Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury. Here's an excerpt (the article only available to BioCentury subscribers): PCR-based diagnosis of infections can…
The Los Angeles Times featured Dr. Gregory Czarnota’s research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).
Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound.
Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc.,…
Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt:…
U.K. Trade and Investment (UKTI) has posted a Youtube video featuring Canadian companies looking to expand their operations to Britain.
Flybits, a Mars Innovation spin-off company, was among three companies to be profiled:
http://www.youtube.com/watch?v=9VrtJuSkYqY
Flybits is launching a corporate presence in East London’s Tech City, which is also known as the Silicon Roundabout.
At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor.
The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot project, which has produced Encycle Therapeutics.
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca